How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?-Reference-Cited by-同舟云学术

How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?

Published:2021-10-02 Issue:1 Volume:27 Page:184-193
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Urabe Fumihiko^ORCID,Kimura Takahiro,Sasaki Hiroshi,Tashiro Kojiro,Iwatani Kosuke,Yasue Keiji,Aoki Manabu,Sato Shun,Takahashi Hiroyuki,Miki Kenta,Egawa Shin

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02040-5.pdf

Reference25 articles.

1. Mottet, N. et al. (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European urology 79(2), 243-262. https://doi.org/10.1016/j.eururo.2020.09.042.

2. Serrano, N. A. & Anscher, M. S. Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations. Oncology (Williston Park, N.Y.) 30, 229-236 (2016).

3. Urabe F et al (2021) Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer Prost Dis. https://doi.org/10.1038/s41391-021-00372-x

4. Skove SL et al (2017) Timing of prostate-specific antigen nadir after radical prostatectomy and risk of biochemical recurrence. Urology 108:129–134. https://doi.org/10.1016/j.urology.2017.07.009

5. Soyano T et al (2021) Time to achieve a prostate-specific antigen nadir of ≤0.2 ng/mL and related factors after permanent prostate brachytherapy. Brachytherapy 20(1):29–37. https://doi.org/10.1016/j.brachy.2020.07.006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with PSA below 0.2 ng/mL at 8 years post high‐dose‐rate brachytherapy have an extremely low risk of subsequent recurrence;International Journal of Urology;2023-08-31

2. Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer;International Journal of Clinical Oncology;2023-07-11

3. Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy;Anticancer Research;2023-06-23

4. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy;International Journal of Clinical Oncology;2023-02-22

5. Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer;In Vivo;2023